Perspective Therapeutics (CATX) Research & Development (2010 - 2026)

Perspective Therapeutics has disclosed Research & Development across 17 years of filings, most recently posting $21.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $21.4 million, up 49.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.3 million (up 88.08% YoY), and the FY2025 annual result was $84.2 million, up 102.26% from the prior year.
• Research & Development came in at $21.4 million for Q1 2026 at Perspective Therapeutics, down from $32.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $32.9 million in Q4 2025 to a low of $468000.0 in Q4 2022.
• The 5-year median for Research & Development is $7.5 million (2024), against an average of $10.1 million.
• Across the five-year window, Research & Development fell 12.52% in 2022 and jumped 1412.82% in 2023, its largest moves.
• Perspective Therapeutics' Research & Development stood at $468000.0 in 2022, then surged by 1412.82% to $7.1 million in 2023, then soared by 81.96% to $12.9 million in 2024, then surged by 155.56% to $32.9 million in 2025, then tumbled by 35.09% to $21.4 million in 2026.
• The last three Research & Development figures came in at $21.4 million (Q1 2026), $32.9 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.